SCHEMBL3791075

SCHEMBL3791075

C=C(C)c1cc(OC)cc(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.55
PDE4A P27815 3/20 0.50
PDE4B Q07343 3/20 0.50
PDE4C Q08493 3/20 0.50
PDE4D Q08499 3/20 0.50
ABCG2 Q9UNQ0 1/20 0.46
NQO2 P16083 1/20 0.42
CYP1A1 P04798 1/20 0.42
CYP1B1 Q16678 1/20 0.42
MAPT P10636 1/20 0.42
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
CYP3A4 P08684 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ABL1 P00519 1/20 0.40
ABCB1 P08183 1/20 0.40
BCR P11274 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12663239 0.87 PDE4A (0.41) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL22991518 0.85 PDE4A (0.40) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL309826 0.85 PDE4A (0.40) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL40552 0.79 ALDH1A1 (0.61) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL30854918 0.78 NPC1 (0.63) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL1790008 0.78 NPC1 (0.63) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL9731581 0.78 ALDH1A1 (0.46) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL2899096 0.75 MAPT (0.63) ALDH1A1MAPTKDM4ESMN1; SMN2MAPK1
SCHEMBL1792104 0.75 MAPT (0.63) ALDH1A1MAPTKDM4ESMN1; SMN2MAPK1
SCHEMBL863160 0.75 MAPK1 (0.56) ALDH1A1PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012018662-A2 FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS SCHERING CORPORATION (US) 2012-02-09 WO disclosed
US-7687145-B2 Compounds containing a thiol protected group bonded to a protecting group via a polarized bond, and structure comprising the compounds on its surface THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-03-30 US disclosed
US-20060273306-A1 Compounds and methods for nanoscale patterning and structure formation THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2006-12-07 US disclosed
US-4290943-A Method of preparing polypeptides MAX-PLANK-GESELLSCHAFT (DE) 1981-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060273306-A1 Compounds and methods for nanoscale patterning and structure formation AS3MT, MPST, TST ALDH1A1 231/4885PDE4A 4416/4885PDE4B 4460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.